LEXICON PHARMACEUTICALS INC. - COMMON STOCK

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

05 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

31 Oct 2024 18:54:54 By Nasdaq GlobeNewswire

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

23 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

22 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

16 Oct 2024 16:35:00 By Nasdaq GlobeNewswire

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

27 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

16 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

10 Sep 2024 08:00:01 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

03 Sep 2024 16:00:00 By Nasdaq GlobeNewswire

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

03 Sep 2024 08:00:01 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

21 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

13 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

07 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

01 Aug 2024 16:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

25 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

16 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

15 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

08 Jul 2024 09:15:00 By Nasdaq GlobeNewswire